BLOG

CURE_20th_anniversary_logo

Launching of Early-Phase Trial May Mark a ‘Major Milestone’ for Improving Gastric and Pancreatic Cancer Treatment

The first patient has been dosed in the ongoing phase 1/2 CLAUDIO-01 clinical trial examining a new antibody drug conjugate called SOT102 in patients with gastric and pancreatic cancer, according to SOTIO, the manufacturer of the drug.